UroGen Pharma Ltd. reported third quarter 2025 financial results with total revenue of $27.5 million, up from $25.2 million in the same period last year. For the nine months ended September 30, 2025, revenue reached $72.0 million, compared to $65.8 million for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $127.4 million, down from $241.7 million at December 31, 2024. Total assets stood at $185.0 million, with total liabilities at $300.5 million and a total shareholders' deficit of $115.4 million. ZUSDURI achieved net product revenue of $1.8 million in the third quarter, with preliminary October demand revenue estimated at $4.5 million. JELMYTO recorded net product revenue of $25.7 million in the third quarter, reflecting a 13% year-over-year growth in underlying demand revenue. UroGen expects full-year 2025 operating expenses to range from $215 to $225 million, including $11 to $14 million in non-cash share-based compensation expense. The company also noted the FDA agreement to submit a New Drug Application for UGN-103, following results from the Phase 3 UTOPIA trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569775-en) on November 06, 2025, and is solely responsible for the information contained therein.
Comments